Treatment

Idiopathic Pulmonary Fibrosis

(ILD Orphan Drug Designation)

No Adverse Events Reported

Pulmonary Fibrosis & IPF

(ILD Orphan Drug Designation)

No Adverse Events Reported

Cystic Fibrosis

(ILD Orphan Drug Designation)

Long COVID Treatment

(No Adverse Events Reported)

Influenza Treatment & Preventative

(No Adverse Effects)

Unmet Needs – Congestion, Allergic

Rhinitis, COPD, Asthma for Diabetic,

Hypertensive, Pregnant - No Steroids

COPD and Asthma - All Ages

No Adverse Effects

Severe COPD Treatment

(Also Lowered High Blood Pressure)

High Blood Pressure and Pulmonary

Hypertension Treatment

COVID-19 Treatment

(No Adverse Effects)

Racehorses - Increase SaO2

Alzheimer's

Concussions

Cancer Pre-Treatment

Patented OTC Nonsteroidal Nasal Sprays

with no adverse effects for Cough, Cold,

Allergy, Sinus, Flu

Patented OTC Nasal Spray sold US/China

To Date: (28) Sets of Human Clinical Trials

completed. (6) Peer Reviews.

EmphyCorp, Inc.

EmphyCorp N115 Rx Nasal and Oral Spray Drug Pipeline w/ No Side Effects 6/3/2025

Drug

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Sprav

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray

N115 Non-Steroidal

Nasal Spray w/ no

adverse effects

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal & Oral Spray

N115 Non-Steroidal

Nasal Spray

N115 Nonsteroidal

Nasal Spray

N115 Nasal Spray

N115 Nasal Spray

and Oral Spray

Phase 1

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Χ

Pilot Study

Plan

Χ

Pilot Study

Χ

Х

Χ

Phase 2

Χ

Χ

Orphan Drug

NDA

Χ

Χ

Х

Χ

Χ

Χ

Χ

Pilot Study

Pilot Study

Pilot Study

(3) New Drug Patents for the treatment of all sinus

and lung diseases & slowing/stopping Lung Fibrosis

EmphyCorp has enough Clinical Data for approval

as an OTC Medical Device, including an

Oxymetazoline Nasal Spray without Rebound Effect

(1) US and (3) Chinese Approved Nasal Sprays

Phase 3

X - Pivotal

Phase III for

NDA

Protocol

Ready

Χ

Protocol

Ready

Protocol

Ready

Protocol

Ready

Protocol

Ready

Х

NDA

X

8 Drug Patents (3 New: Hypoxemia & Dyspnea & Coughing, Apoptosis of Myofibroblasts, Coronavirus/Flu) (x = completed) **Note**

73% Reduction in Coughing

& Improved Lung Function

(Hypoxemia, Dyspnea)

Met (8) Medical Endpoints.

Clinically & Statistically

Significant Results

FEV1, Coughing, Hypoxemia,

Dyspnea, and Sleeping Better Expanded Phase III in 2025.

Met (8) Medical Endpoints

Increases Nasal Nasal Nitric

Oxide to kill Viruses/Shut IL-6

Safe Non-Steroidal

for 30 to 60 Million People

in US Alone

FEV1, Coughing, Hypoxemia,

Dyspnea

Also reduced High Blood Pressure to Normal Levels

Discovered in Phase II Severe

COPD Patient Clinicals

Increases Nasal Nitric Oxide

to kill Viruses/Shut IL-6

Stops Nasal Bleeding

(8) Drug Patents and Multiple

Patented Formulations

3 Million Patients Treated

(8) Drug Patents